therapeutic action: promotion of synaptogenesis

Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study

Researchers investigated whether psilocybin, a compound from certain mushrooms, could be safely used to treat memory problems in older adults with mild cognitive impairment. In this early-stage study, participants received either psilocybin or a placebo while researchers used brain imaging to measure changes in synaptic connections. The preliminary results suggest psilocybin was well-tolerated with manageable side effects like dizziness, and participants were able to complete the study without serious problems.

Read More »

Butyrate ameliorates quinolinic acid–induced cognitive decline in obesity models

This research shows that overweight and obese individuals have higher levels of a toxic compound called quinolinic acid in their bodies, which is linked to memory problems and brain shrinkage. The good news is that butyrate, a substance naturally produced by gut bacteria when we eat fiber, can protect against these harmful effects. Butyrate works by activating genes that produce brain-derived neurotrophic factor (BDNF), a protein essential for brain health and memory formation. The study suggests that increasing butyrate through diet or supplements could help prevent cognitive decline associated with obesity.

Read More »
Scroll to Top